LEXINGTON, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health, today announced that the Company’s T2Candida^® Panel for rapid sepsis detection and T2 Magnetic Resonance (T2MR^®) technology for detecting early-stage Lyme disease were the focus of several poster presentations during IDWeek 2016. The meeting, hosted by the Infectious Diseases Society of America (IDSA) took place from October 26 – 30 in New Orleans, LA.

“The data presented at IDWeek 2016 is compelling and further demonstrates the power of T2MR technology to improve patient care and deliver strong economic returns to hospital systems,” said John McDonough, president and CEO of T2 Biosystems. “Customer success stories, like the ones we saw at IDWeek, will be important for T2 as we drive further adoption of our technology and work to enter our next phase of growth.”

Key Highlights

• T2MR improves the timely management of candidemia, as evidenced by the following results of a 142 candidemic patient-study at Henry Ford Hospital:
  • T2MR testing reduced the time to Candida species identification by 16.5 hours;
  • T2MR testing reduced the time to appropriate antifungal therapy by 13 hours;
  • T2MR testing reduced median intensive care unit (ICU) length of stay (LOS) by seven days;
  • T2MR testing showed a trend in reduction of total LOS by four days; and
  • T2MR resulted in a $1.9 million ROI and $2.3 million in cost savings annually based on T2Candida testing.
• Utilization of the T2Candida Panel reduces duration of antifungal therapy (DOT) and average time to de-escalation, as evidenced by the following results from a study in 160 patients at Huntsville Hospital:
  • Average DOT for patients with a negative T2Candida Panel result was four days;
  • Average time to de-escalation was 42.6 hours;
  • Reduction in DOT and time to de-escalation equated to $280 saved per patient; and
  • The investigators concluded the T2Candida Panel demonstrated greater sensitivity compared to blood culture to detect Candidemia at their facility and provided a much faster time to antifungal treatment modification.
• Candidemia early detection using T2Candida Panel resulted in reduced time to appropriate antifungal therapy, as demonstrated in the following results from a study of 59 patients at Riverside Hospital:
  • For the eight patients on antifungal therapy with negative T2Candida Panel results, antifungal therapy was discontinued in accordance to clinical status in all patients;
  • Of the patients with positive T2Candida Panel results, prior to their positive test results, none were being treated for candidemia;
  • Results from the assay were available in the hospital reporting system in an average of 6.3 hours; and
  • 83 percent of the positive patients received appropriate therapy within six hours and 100 percent within nine hours.
• T2MR detection can be used to rapidly detect the three major Borrelia species causing Lyme disease in whole blood, as well as detect B. burgdorferi in some cases in the absence of positive serology results, as demonstrated in a T2 Biosystems study showing the following:
  • Limits of detection (≥95 percent hit rate for n≥40 replicates) were eight cells/mL for B. burgdorferi and B. garinii and 5 cells/mL for B. afzelii with no incidence of false positives; and
  • Among the 24 most probable clinical samples – classified by at least two positive EIA, WB, or PCR tests – 42% were positive for B. burgdorferi by T2MR.
    • Five cases with EM and negative EIA or WB result were positive by T2MR.
    • Two cases with EM and initial negative or equivocal EIA results that later seroconverted in a return visit were positive by T2MR.
    • In 20 samples tested with PCR and T2MR, agreement was found on one positive and 13 negative samples; T2MR detected Borrelia in seven samples reported negative by PCR.

About T2 Biosystems
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit www.t2biosystems.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the performance of the Company's diagnostic products and the ability to bring such products to market. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. For more information on risk factors for T2 Biosystems, Inc.’s business, please refer to the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 9, 2016, under the heading “Risk Factors,” and other filings the Company makes with the Securities and Exchange Commission from time to time.  Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.

Media Contact:
Susan Heins, Pure Communicationssusan@purecommunicationsinc.com
864-346-8336

Investor Contact:
Matt Clawson, Pure Communicationsmatt@purecommunicationsinc.com
949-370-8500